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INTRODUCTION
Benign bone tumors and tumor-like bone lesions are 
relatively rare diseases that mainly affect children and 
young adults, whose skeleton is still undergoing forma-
tion. These diseases can cause fractures, bone and joint 
deformities and gait disorders, and sometimes leave 
disabling sequelae for life.
Once the tumor has been diagnosed, it must be 
staged with a view to treatment. Enneking was the first 
to describe a staging system for benign bone tumors and 
nowadays this is the most commonly used system(1-5).
This staging system introduced a unique language to 
evaluate and compare the results from different patient 
protocols and patient series from different treatment 
centers. 
ABSTRACT
Objective: To evaluate the efficacy of the Enneking staging sys-
tem for determining the prognosis, planning surgical treatment 
and indicating adjuvant therapy for benign bone tumors (BBT) 
and tumor-like bone lesions (TBL). Methods: A retrospective 
multicenter, descriptive, nonrandomized study was carried out 
on a representative sample comprising a large series of 165 
patients with a total of 168 benign bone tumors and tumor-
like bone lesions. The patient sample was typical, and matched 
the literature in all respects. All the patients were classified 
according to the Enneking staging system, and the initial stag-
ing of each lesion was correlated with its behavior after either 
conservative or surgical treatment, in order to determine the 
efficacy of the system. The treatment options and complica-
tions were described and analyzed. Results: The results from the 
treatment provided 95.2% agreement with the Enneking staging 
system, with a 95% confidence interval of between 90.8 and 
97.9%. Of the 168 tumors treated, only eight (4.8%) could not 
be controlled in relation to the initial treatment indicated by 
the Enneking staging system. Tumors classified as active were 
the most prevalent, comprising 73.2% of the lesions. Tumor 
recurrence was significantly more frequent (p < 0.001) in the 
aggressive stage. All the patients staged as latent evolved to 
cure. The study suggested that surgery with wide margins, for 
aggressive lesions, could provide better lesion control, with a 
lower recurrence rate (p > 0.001). For latent and active lesions, 
the study demonstrated the efficacy of both expectant treatment 
and excision, with or without autogenous bone graft. Conclu-
sion: The results confirm that the Enneking staging system was 
very efficient in determining the prognosis, enabling surgical 
planning and indicating adjuvant therapy for treatment of BBT 
and TBL.
Keywords – Bone diseases; Bone neoplasms/diagnosis/epide-
miology/ pathology/radiography/surgery; Neoplasm staging
By linking the tumor stage to surgical margins, the 
surgical procedure indicated for achieving control and 
cure for the lesion can be obtained(3,4).
The Enneking staging system was published in the 
1980s(1-5) and studies are needed to test it, verify its ef-
ficacy and refine it(6) (Table 1).
The objective of this study was to evaluate the ef-
ficacy of the Enneking staging system for determining 
the prognosis, planning surgical treatment and indicat-
ing adjuvant therapy, in order to manage benign bone 
tumors and tumor-like bone lesions.
METHODS
A descriptive observational study was carried out on 
a large series of cases. The study was nonrandomized, 
© 2010 Sociedade Brasileira de Ortopedia e Traumatologia. Open access under CC BY-NC-ND license.
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Table 1 – Enneking staging system: linkage between stages and 
surgical margins
Tumor stage
(benign)
Grade, location, 
metastases
Clinical 
evolution
Control margin
1 GoToMo Latent Intracapsular
2 GoToMo Active
Marginal or intracapsular 
plus effective adjuvant 
3 GoT1-2M0-1 Aggressive
Wide or marginal plus 
effective adjuvant
Go = Benign, To = Intracapsular, T1 = Extracapsular, Intracompartmental, T2 = Extracapsular, 
Extracompartmental, Mo = Absence of metastases M1 = Presence of metastases.
retrospective and multicenter. The data were gathered 
by the author from medical records and imaging ex-
aminations on patients treated at the IPSEMG Hospi-
tal, the Orthopedic-AMR Hospital, the Belo Horizonte 
Hospital and the São Francisco de Assis Hospital, all 
in Belo Horizonte, Minas Gerais. The imaging exams 
consisted of simple radiographs, computed tomography, 
nuclear magnetic resonance, scintigraphy and arteriog-
raphy. The sample was formed by 165 patients, with 
168 tumor lesions, who underwent either outpatient 
conservative treatment or hospital surgical treatment 
(Tables 2 and 3).
One patient with multicenter giant cell tumor pre-
sented four lesions. Among the patients with osteochon-
droma, there were four cases of osteochondromatosis. 
Only one patient, with giant cell tumor, presented lung 
metastases. These were patients treated consecutively 
by the author over a 16-year period, between January 
1988 (which was when the Enneking staging system 
came into use) and January 2004. For patients to be 
included in the study, the minimum length of follow-up 
required was three years.
The patients’ mean age was 23.2 years. The young-
est patient was three years old and presented osteoid 
osteoma, and the oldest was 69 years old, presenting 
enchondroma. There were 82 male patients and 83 fe-
male patients. The femur was the bone most affected, 
accounting for 40% of the lesions, followed by the tibia, 
with 20%. Other highly affected bones were the hu-
merus, fibula, iliac and radius. The maximum length 
of follow-up was 19 years and the minimum was three 
years, with a mean of 8.35 years. 
Considering the stages, 36 patients were latent (B1), 
123 were active (B2) and nine were aggressive (B3). 
Among the aggressive ones, five were giant cell tumors 
and four were aneurysmatic bone cysts.
Thirty-nine tumors were treated conservatively and 
another 129 were treated with surgically. Adjuvant thera-
py was used for 30 tumors, using polymethylmethacrylate 
(PMMA) cement in 29 cases and radiotherapy in one.
The conservative treatment consisted of clinical-
radiological observation in 29 cases and immobiliza-
tion with plaster casts for fractures in ten cases. The 
surgical treatment followed the linkage between the 
stages and the surgical margins of the Enneking staging 
system (Table 1). The treatment methods are described 
in Table 4 and the surgical margins that were used are 
described in Table 5.
Widening the margin using a high-speed rotary drill 
was carried out in all the cases of intralesional exci-
sion, as well as electrocauterization of the cavity. In 
six cases, multiple Kirschner wires were inserted into 
the cementation. Autogenous iliac bone grafts was used 
in 29 cases and homologous grafts in two cases. Bone 
slippage was performed in one case. One patient with a 
pelvic aneurysmatic bone cyst was treated with selective 
arterial embolization and radiotherapy. Anatomopatho-
logical examinations were performed on all the patients 
who underwent open treatment.
Table 2 – Benign bone tumors
Number of patients
Osteochondroma 31
Enchondroma 14
Giant cell tumors 13
Chondroblastoma 12
Osteoid osteoma 10
Chondromyxoid fibroma 2
Intraosseous lipoma 2
Benign fibrous histiocytoma 1
Total 85
Source: SAME HGIP, HO, HBH, HSF, 2008.
Table 3 – Tumor-like bone lesions
Number of patients
Non-ossifying fibroma 25
Simple bone cyst 19
Fibrotic dysplasia 17
Aneurysmatic bone cyst 10
Ossifying myositis 6
Hyperparathyroidism 3
Total 80
Source: SAME HGIP, HO, HBH, HSF, 2008. 
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All the patients were staged using the Enneking 
staging system and the treatment performed, surgical 
margins obtained and whether any adjuvant was used 
were identified. The date when treatment started was 
also determined, together with the minimum follow-up 
of three years, treatment results and presence of relapses 
and cure. Subsequently, a correlation between the ini-
tial staging of each lesion and its behavior during the 
follow-up was made in order to determine the efficacy 
of the Enneking staging system for predicting the prog-
nosis, planning the surgical treatment and indicating 
adjuvant therapy. 
The criterion for determining whether cure was 
achieved was the clinical-radiological condition after 
three years of follow-up. To verify relapses, imaging 
examinations or anatomopathological examinations af-
ter reoperation were used.
For a population to be considered large, the sample 
requires 141 patients. With a sample of 165 individuals, 
medium effect, significance level of 5% and two degrees 
of freedom, the power of this study was 94%. With only 
one degree of freedom, the power was 97%.
Table 4 – Surgical treatment methods
Type Number of cases
Simple excision 40
Excision and bone graft 31
Excision and cementation 29
Biopsy alone 8
Infiltration with corticoid 8
Osteosynthesis 7
Joint prosthesis 5
Segmental excision 3
Arthrodesis 1
Total 132
Source: SAME HGIP, HO, HBH, HSF, 2008.
Table 5 – Surgical margins used
Type Number of cases
Intracapsular 53
Marginal 71
Wide 5
Total 129
Source: SAME HGIP, HO, HBH, HSF, 2008.
The statistical analysis consisted of the chi-square 
test, Fisher’s exact test and calculation of the confi-
dence intervals for the percentage of agreement. In all 
the analyses, the significance level was taken to be 5% 
or 0.05. 
A bibliographic review was conducted in the Med-
line and Lilacs databases was carried out over a ten-year 
period, between January 1997 and December 2006. In 
total, 450 abstracts on this topic were found, from which 
100 studies with the complete text were chosen. These 
studies presented the best methodologies and levels of 
scientific evidence. In addition to these texts, the clas-
sic studies on this topic were selected, regardless of the 
publication date. 
The present project was approved by the Research 
Ethics Committee of the IPSEMG Hospital (HGIP).
RESULTS 
The results from the treatment showed a high per-
centage of agreement with the Enneking staging sys-
tem, with regard to three parameters of determining 
the prognosis, surgical planning and adjuvant therapy 
(Table 6).
Table 6 – Agreement between the treatment results and the 
Enneking staging system (ESS) in relation to the prognosis, 
surgical planning and adjuvant therapy.
ESS 
Prognosis Surgical planning Adjuvant therapy
n (1) % n % n %
Yes 160 95.2% 121 93.8% 26 86.7%
No 8 4.8% 8 6.2% 4 13.3%
Total 168 100.0% 129 100.0% 30 100.0%
(1) n = Number of cases
The overall analysis, including all the tumors, showed 
an agreement rate of 95.2% between the treatment and 
the Enneking staging system, with a 95% confidence 
interval for this proportion that ranged from 90.8 to 
97.9% (Table 7 and Figure 1). 
The final results from the treatment showed that out 
of the 168 tumors treated, only eight (4.8%) were not 
brought under control with the initial treatment indi-
cated by the Enneking staging system (Table 7). Clini-
cally, out of the 165 treated patients, 159 were cured or 
became asymptomatic, four presented symptoms and 
two died. 
49
EFFICACY OF THE ENNEKING STAGING SYSTEM IN RELATION
TO TREATING BENIGN BONE TUMORS AND TUMOR-LIKE BONE LESIONS
Rev Bras Ortop. 2010;45(1):46-52
80
82
84
86
88
90
92
94
96
98
100
Benign Bone
Tumors
Tumor-Like
Bone Lesions
Total
P
e
rc
e
n
ta
g
e
 o
f 
A
g
re
e
m
e
n
t
Figure 1 – 95% confidence intervals for the estimated percent-
age agreement in each group
Table 7 – Agreement between the treatment results relating to 
benign bone tumors and tumor-like bone lesions and the Ennek-
ing staging system (ESS)
ESS
Benign bone tumors
Tumor-like bone 
lesions
Total
n (1) % n % n %
Yes 85 96.6% 75 93.8% 160 95.2%
No 3 3.4% 5 6.2% 8 4.8%
Total 88 100.0% 80 100.0% 168 100.0%
(1) n = Number of cases
Group
Agreement 
proportion
95% confidence interval for 
the proportion (%)
Benign bone tumors 96.6 90.4 – 99.3
Tumor-like bone lesions 93.8 86.0 – 97.9
Total 95.2 90.8 – 97.9
Note: By definition, the confidence interval for a proportion is not symmetrical around the esti-
mated value for the proportion, as it would be in the case of a confidence interval for a mean
When dividing the tumors according to stages, the 
active type (B2) predominated, with 73.2% of the le-
sions, leaving the latent stage (B1) with 21.4% and the 
aggressive stage (B3) with 5.4%, as shown in Table 8. 
In this study, simple bone cysts were responsible for 
more than 50% of the diagnoses that were made due 
to a pathological fracture, followed by non-ossifying 
fibroma and fibrotic dysplasia. 
Out of the 129 patients who underwent surgery, there 
were eight relapses (four B2 and four B3), as shown in 
Table 9, and an overall rate of 6.2% (Table 6).
The relapses were more frequent in the aggressive 
stage (B3) with a rate of 44.4% (four out of nine pa-
tients). Giant cell tumors were included among these, 
with three relapses staged as B3, out of 16 treated 
tumors, resulting in a rate of 18.75%. No active (B2) 
giant cell tumor relapsed. For patients with operat-
ed giant cell tumors by means of marginal surgery 
and cementation, the relapse rate was 30% (three B3 
cases from a total of ten). These three patients were 
operated again. One underwent wide surgery, had 
a shoulder endoprosthesis implanted and achieved 
cured. Another presented a second relapse in margin-
al surgery with cementation and then a third relapse 
and was lost from the follow-up after wide surgery 
and replacement with a fibular graft for a distal tu-
mor of the radius were indicated. The third patient 
presented primary malignant transformation to fem-
oral fibrosarcoma and was treated with a femoral 
 endoprosthesis. 
The four B2 tumors that relapsed (rate of 3.3%; 
four out of 123 cases) presented simple bone cysts 
of the femoral neck, fibrous dysplasia of the humeral 
diaphysis, dysplasia of the femoral neck and aneurys-
matic bone cyst of the femoral neck (Tables 8 and 9). 
All of these patients underwent reoperation and were 
cured by means of intracapsular surgery and autog-
enous bone grafts.
Table 8 – Agreement according to stages, between the treatment 
results and the Enneking staging system (ESS)
ESS
Latent Active Aggressive Total
n (1) % n % n % n %
Yes 36 100.0% 119 96.7% 5 55.6% 160 95.2%
No 0 0.0% 4 3.3% 4 44.4% 8 4.8%
Total 36 100.0% 123 100.0% 9 100.0% 168 100.0%
(1) n = Number of cases
The earliest relapse occurred after six months and the 
last was after five years, with a mean of 23.75 months 
for the eight relapsed cases (Table 9). 
All the patients staged as latent (B1) evolved towards 
cure, with a rate of 100% (Table 8). 
The adjuvant therapy with PMMA cement presented 
only three relapses (10.3% ) out of 29 operated cases. 
The three tumors were giant cell tumors staged as B3.
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Among the nine patients staged as B3, five did not 
relapse (two with giant cell tumors and three with an-
eurysmatic bone cysts). Four of these underwent opera-
tions with wide surgery and one with marginal surgery. 
In addition, three underwent prosthetic substitution, one 
underwent bone grafting with slippage and another un-
derwent marginal surgery plus cementation (Table 10).
A patient with pelvic aneurysmatic bone cyst (B3) 
who was treated with selective arterial embolization and 
radiotherapy presented secondary malignant transfor-
mation to fibrosarcoma, five years after the treatment. 
The two tumors that became malignant evolved to fib-
rosarcomas that were staged as II-B. This patient under-
went reoperation with wide surgical margins, femoral 
endoprosthesis for giant cell tumor in the distal femur 
and pelvic resection for aneurysmatic bone cyst in the 
iliac wing. After this procedure, the patient was treated 
with chemotherapy, but presented pulmonary metastasis 
and progressed to death.
Table 9 – Relapses
Name Type Gender Age Staging Surgery Relapse
1. RDS GCT M 19 B3 Marginal (proximal humerus) + PMMA adjuvant 14 months
2. DSG GCT M 27 B3 Marginal (distal radius) + PMMA adjuvant 11 months
3. GGT GCT F 38 B3 Marginal (distal femur) + PMMA adjuvant
6 months (malignant 
transformation)
4. BHOM SBC M 5 B2 Intracapsular (femoral neck) 17 months
5. AJT FD F 23 B2 Intracapsular (femoral neck) + autogenous bone graft 48 months
6. ASS FD F 32 B2 Intracapsular (humerus diaphysis) + autogenous bone graft 22 months
7. CCCR ABC M 5 B3 Intracapsular (iliac wing) + embolization + radiotherapy
60 months (malignant 
transformation)
8. RCB ABC M 10 B2 Intracapsular (proximal femur) + autogenous bone graft 12 months
Source: SAME HGIP, HO, HBH, HSF, 2008.
PMMA = Polymethylmethacrylate; GCT = Giant cell tumor; SBC = Simple bone cyst; FD = Fibrotic dysplasia; ABC = Aneurysmatic bone cyst
Table 10 – Aggressive tumors (B3) that did not relapse
Name Type Gender Age Staging Surgery
1.VCA GCT F 15 GoT2Mo Marginal knee (tibia) + bone cement
2. JRA GCT F 13 GoT2M1 Wide + knee endoprosthesis + thoracotomy
3. AJOR ABC M 30 GoT2Mo Wide + knee endoprosthesis
4. CAMS ABC M 29 GoT2Mo Wide + total hip prosthesis
5. EFA ABC M 17 GoT2Mo Wide + ankle bone graft and slippage (tibia)
Source: SAME HGIP, HO, HBH, HSF, 2008.
The patient with multicenter giant cell tumor, with 
four epiphyseal lesions in the same lower limb, and 
another patient who presented pulmonary metastasis 
due to giant cell tumor, underwent thoracotomy and 
were cured.
The most common late complications were: four 
cases of lower-limb shortening in three patients with 
aneurysmatic bone cyst and one with fibrotic dyspla-
sia, which were related to angular deformity and in-
volvement of the growth plate; five cases of arthrosis, 
of which one was related to angular deformity due to 
fibrotic dysplasia and four occurred after cementation 
due to giant cell tumors: in the knee (proximal tibia, 
two cases), in the subtalar (calcaneal tumor) and in 
the wrist (distal radius tumor). There was only one 
case of late deep infection, in enchondroma of the 
proximal tibia that had been operated with cemen-
tation, and it was necessary to remove the cement 
(Table 11).
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Table 11 – Complications
Number of cases
Late arthrosis 5
Difference between limbs 4
Malignant transformation 2
Joint limitation 2
Varus deformity 2
Superficial infection 2
Femoral fracture 2
Genu valgum 1
Tendon rupture 1
Deep infection 1
Meralgia paresthetica 1
Hip bursitis 1
Source: SAME HGIP, HO, HBH, HSF, 2008.
DISCUSSION
The sample of this study was typical and was in 
agreement with the literature in all respects: most fre-
quent tumors, age, sex and bones most affected(7,8). The 
minimum follow-up for inclusion in the study was three 
years, because these lesions generally present relapse 
within the first two years after treatment(9-11).
Lesions in the active stage (B2) predominated, and 
simple bone cysts were diagnosed most frequently, by 
means of fractures. Clinical practice shows that most 
lesions that require medical attention, since they are 
symptomatic and cause fractures, are active benign 
lesions(12). 
It was also noted that the chances of failure of the 
surgical treatment, with consequent tumor relapse, in-
creased through evolving from the latent stage (B1) to 
the active stage (B2) and progressively to the aggres-
sive stage (B3), with statistical significance (p < 0.001) 
(Table 8). This study showed that bone cement (PMMA) 
was an effective adjuvant when associated with marginal 
surgery (Table 6). For the patients with giant cell tumors 
operated with cementation, the relapse rate was high, but 
similar to the findings of other published authors(9,13,14). 
Greater reoccurrence among tumors staged as B3 is in 
agreement with some authors(9,15), although others did 
not find a similar result(10,16).
This study suggests that surgery with wide margins 
for aggressive (B3) benign lesions could control the le-
sion better, since it did not leave residual microscopic 
disease and presented a lower relapse rate. However, 
because of the small sample at this stage, this informa-
tion was not statistically significant (p > 0.001) (Tables 
9 and 10). This affirmation is in agreement with the 
literature, in which it is reported that surgery, initially 
with wide margins, could reduce the risk of relapses, but 
at the cost of loss of function. For this reason, surgery 
with wide margins is not the preferred method and the 
risk of possible relapses is accepted(6,8,17). 
Apart from the two patients who evolved to malig-
nant tumors and another patient who was lost from the 
follow-up, all the patients staged as B3 were cured, thus 
suggesting that the treatment was effective.
The absence of relapses in cases of latent tumors 
(B1) and the low rate of relapses for active lesions (B2) 
attest to the efficacy of expectant treatment and exci-
sion with or without autogenous iliac bone graft. This 
is corroborated by the literature(7,8). 
An analysis on the eight patients who presented re-
lapses showed that the two patients whose tumors be-
came malignant probably would not have been brought 
under control by any kind of treatment, since these cases 
were of high-grade fibrosarcoma (II-B)(1-5). One patient 
with giant cell tumor (B3) of the distal radius, who was 
lost from the follow-up could have been controlled with 
wide surgery and replacement with a fibular graft, as 
shown in the literature(7,8), although there have been re-
ports that giant cell tumors of the distal radius are more 
aggressive(9,10). Four patients were cured by means of 
intracapsular reoperation with autogenous bone grafts. 
One patient with giant cell tumor (B3) of the proximal 
humerus was cured with wide surgery and replacement 
with an endoprosthesis (Table 9).
Complications such as primary malignant transforma-
tion and secondary transformation on radiotherapy(18,19), 
pulmonary metastasis due to giant cell tumors(20) and 
multicenter presentation of giant cell tumors(21) are well 
described in the literature. Post-cementation late ar-
throsis was not found by some authors(10,15,22), but has 
been described by others, who have suggested using 
subchondral bone grafts to protect the cartilage(22). 
The Enneking staging system is a surgical staging 
system that was created to serve as a guide for surgical 
treatment of musculoskeletal tumors. It was tested and 
adopted in 1980 by the Musculoskeletal Tumor Society 
(MSTS)(1,2) and by the American Joint Committee for 
Cancer Staging and End Results Reporting (AJCC)(23). 
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The system was created at a time when simple radio-
graphs were the only imaging examination used to stage 
patients. Up until now, this staging system has not been 
modified. It has remained unaltered for more than 25 
years, over a period with great advances in imaging 
methods, genetics, molecular oncology, adjuvant ther-
apy, bone grafting and surgical techniques(24). 
From surveying the available literature, it can be 
seen that this staging system has not been statistically 
validated through broad-based multicenter studies. In 
2002, the AJCC, which was using the Enneking sys-
tem, made modifications to the staging of sarcomas, 
by replacing the compartmental location by the size of 
the tumor and dividing the patients into three catego-
ries: skip metastasis, pulmonary metastasis and other 
metastasis(25,26). 
The results from the present study confirmed that 
the Enneking staging system was very effective in de-
termining the prognosis, planning the surgery and in-
dicating the adjuvant therapy for benign bone tumors 
and tumor-like bone lesions (Tables 6 and 7). This is 
the only system for benign bone lesions that exists and, 
to our knowledge through reviewing the literature, no 
studies on its validation have been published.
Although this study had the objective of evaluating 
the system and has proven its efficacy so far, we suggest 
that multi-institution studies, with samples including a 
greater number of patients, should be carried out in or-
der to reevaluate the system and, possibly, to modernize 
it in the light of new knowledge.
CONCLUSION 
The Enneking staging system was very effective in 
determining the prognosis, planning the surgery and 
indicating adjuvant therapy for benign bone tumors and 
tumor-like bone lesions.
